Most cited papers from Minnesota Oncology

Minnesota Oncology

What are the most cited papers from Minnesota Oncology?

The most cited paper from Minnesota Oncology is "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial" (Achim Rittmeyer et al., 2016), with 4,817 citations. Next come "Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer" (2,422) and "Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA" (1,567).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 58 papers. Every paper with more than 147 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Achim Rittmeyer et al. · The Lancet Open access	12 Dec 2016	4,817
2	Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Robert Allen Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine Open access	28 Dec 2011	2,422
3	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA M.C. Liu et al. · Annals of Oncology Open access159 authors	30 Mar 2020	1,567
4	A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG Database Paul W. Sperduto, Brian A. Berkey, Laurie E. Gaspar et al. · International Journal of Radiation OncologyBiologyPhysics	14 Nov 2007	1,052
5	Diagnosis-Specific Prognostic Factors, Indexes, and Treatment Outcomes for Patients With Newly Diagnosed Brain Metastases: A Multi-Institutional Analysis of 4,259 Patients Paul W. Sperduto, Samuel T. Chao, Penny K. Sneed et al. · International Journal of Radiation OncologyBiologyPhysics	28 Nov 2009	991
6	Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia Tait D. Shanafelt et al. · New England Journal of Medicine Open access	31 Jul 2019	751
7	Estimating Survival in Patients With Lung Cancer and Brain Metastases Paul W. Sperduto et al. · JAMA Oncology Open access	28 Nov 2016	668
8	Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline May N. Tsao, Dirk Rades, Andrew Wirth et al. · Practical Radiation Oncology Open access	31 Jan 2012	592
9	Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin Peter Ferenci, Michael Fried, Mitchell L. Shiffman et al. · Journal of Hepatology	Jun 2005	517
10	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient Paul W. Sperduto et al. · Journal of Clinical Oncology Open access	15 Sep 2020	483
11	Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices Ratti Ram Sharma, Kathryn Pollock, Allison Hubel et al. · Transfusion Open access	16 Oct 2013	453
12	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) Kathleen N. Moore et al. · Journal of Clinical Oncology Open access	23 Apr 2021	428
13	Survival for older patients with acute myeloid leukemia: a population-based study Betül Oran, Daniel Jordan Weisdorf · Haematologica Open access	6 Jul 2012	426
14	Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study Keith Christopher Bible, Vera Jean Suman, Julian R. Molina et al. · The Lancet Oncology Open access	21 Sep 2010	423
15	Identification of a Gene Expression Signature Associated with Recurrent Disease in Squamous Cell Carcinoma of the Head and Neck Matthew A. Ginos, Grier P. Page, Bryan S. Michalowicz et al. · Cancer Research	2004	408
16	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) Bradley J. Monk et al. · Journal of Clinical Oncology Open access	6 Jun 2022	407
17	Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial Roy S. Herbst, Rafat Ansari, Frederique Bustin et al. · The Lancet Open access	May 2011	393
18	Circulating endothelial cells Alexander Woywodt, Francesco Bertolini, Todd M. Bull et al. · Thrombosis and Haemostasis	2005	391
19	Pericytes and vessel maturation during tumor angiogenesis and metastasis Ahmad Raza, Michael John Franklin, Arkadiusz Zbigniew Dudek · American Journal of Hematology	28 Apr 2010	382
20	Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases Paul W. Sperduto et al. · International Journal of Radiation OncologyBiologyPhysics Open access	19 Apr 2011	379
21	Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial Shannon Neville Westin et al. · Journal of Clinical Oncology Open access256 authors	21 Oct 2023	370
22	Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer John K. Chan, Mark F. Brady, Richard T. Penson et al. · New England Journal of Medicine Open access	25 Feb 2016	370
23	Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen Bree A. Foley, Sarah Cooley, Michael R. Verneris et al. · The Journal of Immunology Open access	18 Oct 2012	366
24	Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion John D. Belcher, Paul H. Marker, Jill P. Weber et al. · Blood	Oct 2000	329
25	Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease Kerry L. Donnelly, Coleman I. Smith, Sarah Jane Schwarzenberg et al. · Journal of Clinical Investigation Open access	2 May 2005	322
26	Mast cell‐neural interactions contribute to pain and itch Kalpna Gupta, Ilkka T. Harvima · Immunological Reviews ReviewOpen access	12 Feb 2018	319
27	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial Robert H.I. Andtbacka, Merrick Ross, Igor J. Puzanov et al. · Annals of Surgical Oncology Open access	24 Jun 2016	310
28	Anisotropic forces from spatially constrained focal adhesions mediate contact guidance directed cell migration Arja Ray, Oscar Lee, Zaw Win et al. · Nature Communications Open access	12 Apr 2017	309
29	Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study Mark F. Kozloff, Marianne Ulcickas Yood, Jordan D. Berlin et al. · The Oncologist Open access	Sep 2009	309
30	Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study Tanios Bekaii‐Saab, Fang‐Shu Ou, Daniel H. Ahn et al. · The Lancet Oncology Open access	28 Jun 2019	291
31	Do Adults Change Their Lifestyle Behaviors After a Cancer Diagnosis? Chris M. Blanchard, Maxine M. Denniston, Frank Baker et al. · American Journal of Health Behavior	May 2003	282
32	Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice John D. Belcher · Journal of Clinical Investigation Open access	17 Feb 2006	267
33	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial Shaji Kunnathu Kumar et al. · The Lancet Oncology Open access	29 Aug 2020	263
34	Heme Degradation and Vascular Injury John D. Belcher, Joan Denise Beckman, György Balla et al. · Antioxidants and Redox Signaling Open access	21 Aug 2009	254
35	Practical clinical interventions for diet, physical activity, and weight control in cancer survivors Wendy Demark‐Wahnefried, Laura Q. Rogers, Catherine M. Alfano et al. · CA A Cancer Journal for Clinicians Open access	13 Feb 2015	254
36	Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial Tait D. Shanafelt et al. · Blood Open access	15 Apr 2022	244
37	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study Barbara M. Norquist et al. · Clinical Cancer Research Open access	30 Nov 2017	238
38	Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370) David Robert Spigel, Craig H. Reynolds, David Michael Waterhouse et al. · Journal of Thoracic Oncology Open access	6 Mar 2018	230
39	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA) Paul W. Sperduto et al. · International Journal of Radiation OncologyBiologyPhysics Open access	16 Oct 2017	214
40	Adhesion Receptors as Regulators of the Hematopoietic Process Catherine M. Verfaillie · Blood Open access	15 Oct 1998	200
41	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma Howard L. Kaufman et al. · Nature Reviews Clinical Oncology ReviewOpen access	27 Aug 2013	199
42	Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer Dylan Michael Zylla, Brett L. Gourley, Derek Vang et al. · Cancer Open access	16 Sep 2013	195
43	A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: A multicenter trial Alan R. Shalita, Jonathan Weiss, Dan K. Chalker et al. · Journal of the American Academy of Dermatology	Mar 1996	187
44	Phase 1/2a, open‐label, multicenter study of RM ‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma David M. Cognetti, Jennifer Maria Johnson, Joseph Curry et al. · Head & Neck Open access	9 Oct 2021	183
45	Cutting Edge: MicroRNA-181 Promotes Human NK Cell Development by Regulating Notch Signaling Frank M. Cichocki, Martin Felices, Valarie McCullar et al. · The Journal of Immunology Open access	15 Nov 2011	181
46	Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial Edward S. Kim, Vamsidhar Velcheti, Tarek M. Mekhail et al. · Nature Medicine Open access	14 Apr 2022	179
47	The influence of social support on depressive symptoms in cancer patients Danette M. Hann, Frank Baker, Maxine M. Denniston et al. · Journal of Psychosomatic Research	May 2002	174
48	Intra-articular treatment of knee osteoarthritis: from anti-inflammatories to products of regenerative medicine Masters M. Richards, Joshua “Shane Maxwell, Lihui Weng et al. · The Physician and Sportsmedicine Open access	17 Mar 2016	171
49	Mometasone Furoate Effect on Acute Skin Toxicity in Breast Cancer Patients Receiving Radiotherapy: A Phase III Double-Blind, Randomized Trial From the North Central Cancer Treatment Group N06C4 Robert Clell Miller, David J. Schwartz, Jeff A. Sloan et al. · International Journal of Radiation OncologyBiologyPhysics Open access	27 Aug 2010	169
50	The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer Paul W. Sperduto, Norbert Kased, David Roberge et al. · Journal of Neuro-Oncology	5 Mar 2013	161

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.